"我们依托启迪清华系创新网络，在北京、合肥等创新枢纽城市设立分站赛，形成跨区域联动、全 要素支持的招引机制。"启迪之星（句容）副总经理徐晶晶介绍，赛事已累计吸引超50个科技项目参 赛，促成7个优质项目落地转化。 政府搭台，平台赋能，项目受益。作为2023"智造句容"产业创新大赛引进重点项目之一，浡芬生物 的核心产品在污水处理领域实现革命性突破。此外，掌握原子级纳米探针技术的安测科技，凭借领先的 半导体检测解决方案赢得2024"智造句容"产业创新大赛三等奖。"获得比赛奖金后，我们决定将产线放 在句容。"句容市安测科技有限公司负责人表示，企业还通过启迪之星（句容）提供的"科技红娘"服务 与句容周边半导体企业建立了联系。 今年，启迪之星（句容）新引进的5家科技企业呈现"落地即起跑"的发展态势。瑞达电气获奖入驻 后，迅速得到启迪之星（句容）的帮助，与开发区企业对接合作；云孪数据则在句容、南京联动服务 下，快速建立在句容的知识产权布局；国芯传感、云孪数据等多家企业已与上海、南京、常州的企业建 立研发协同机制……这种科技成果落地高效转化率，得益于"赛事遴选-政策匹配-生态赋能"的闭环发展 机制。 从孵化企业，到新项目的落 ...

美股盘初，主要行业ETF普涨，半导体ETF、生物科技指数ETF涨幅居前。 | 生物科技指 ... | 119.68 | +2.44 (+2.08%) | 88801股 | 95.03亿 | | --- | --- | --- | --- | --- | | us IBB | | | | | | 半导体ETF --- | 191.58 | +3.75 (+2.00%) | 66.35万股 | 22.65亿 | | us SMH | | | | | | 网络股指数E ... | 210.40 | +4.07 (+1.97%) | 10638股 | 139.71亿 | | us FDN | | | | | | 金融业ETF --- | 46.54 | J +0.89 (+1.95%) | 287.53万股 | 518.01亿 | | us XLF | | | | | | 可选消费ET ... | 183.79 | +3.34 (+1.85%) | 21.18万股 | 230.85亿 | | US XLY | | | | | | 区域银行ET ... | 51.65 | +0.91 (+1.79%) | 97.78万 ...

【SynBioCon】 获 悉， 近日，百开盛生物宣布 瑞鲍迪苷M （Rebaudioside M，RebM）产品正 式通过美国GRAS（一般公认安全）认证， 将为全球食品工业减糖提供"中国方案"。 瑞鲍迪苷M（RebM）是一种天然高倍甜味剂，甜度通常是蔗糖的 200-300 倍。作为一种甜叶菊中的稀有单体，相 比其他甜菊糖苷（如瑞鲍迪苷A），其苦味和后苦味更弱，口感更接近蔗糖，在食品、饮料、膳食补充剂和动物营 养等多个领域展现出广泛的市场应用潜力。 百开盛生物基于独有的酶与生物催化技术平台，实现瑞鲍迪苷生产关键酶的发掘及 定向进化 ，生产 效率相对传统植物合成提高近千倍。 结合自有过程工程技术平台，使所生产的瑞鲍迪苷M产品纯度 （RM≥95%）媲美植物提取，满足高端应用场景需求。 "GRAS"是"Generally Recognized As Safe（一般公认安全）"的缩写, 是美国食品成分的一种重要分类。随着食品技术 尤其是合成生物学技术的不断进步及食品贸易全球化的发展，GRAS认证因其高度的权威性和国际认可度，已成为 众多企业进军国际市场的关键通行证。 参 考 信息 ： 本文素材来自百开盛生物 ，本平 ...

溢多利（300381）公告，为完善和健全公司分红机制，积极回报投资者，切实保护中小投资者的合法权 益，根据相关法律、法规和规范性文件及《公司章程》的相关规定，结合公司的盈利能力、经营发展规 划、股东回报等因素，公司董事会制定了《广东溢多利生物科技股份有限公司未来三年股东分红回报规 划(2025-2027年)》。公司未来三年具体股东回报规划如下：公司可以采取现金或股票等方式分配利润， 利润分配不得超过累计可分配利润的范围，不得损害公司持续经营能力。公司进行现金分红的间隔期限 为一年，董事会可以根据公司的资金状况提议公司进行中期现金分配。在符合《公司法》及相关规定的 前提下，经股东大会决议，公司应当进行利润分配，其中，现金分红优先于股票股利。公司进行利润分 配时，现金分红在本次利润分配中所占的比例不低于百分之二十。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 注：因增加、删除了部分条款，公司章程的条款编号相应变化。 除上述条款修订外，《公司章程》其他条款内容不变。上述事项尚需提请公司2024年年度股东大会审 议。股东大会审议通过后将修改《公司章程》，并授权董事会及其授权的其他人士办理工商变更登记相 关手续。以上事项最终修订结果以工商部门登记、备案结果为准。 三、制定、修订相关制度 为进一步规范公司运作，不断完善公司治理体系，保护投资者合法权益，公司根据《中华人民共和国公 司法》《上市公司章程指引》《上市公司治理准则》《中国证券监督管理委员会关于修改、废止部分证 券期货规范性文件的决定》等相关法律法规、规范性文件的最新规定和要求，公司拟制定相关制度，并 对部分制度进行相应地修订。 ■ 上述《中农立华生物科技股份有限公司独立董事工作细则》《中农立华生物科技股份有限公司董事会议 事规则》《中农立华生物科技股份有限公司对外担保管理制度》《中农立华生物科技股份有限公司募集 资金管理办法》《中农立华生物科技股份有限公司关联交易管理办法》《中农立华生物科技股份有限公 司重大投资决策管理办法》《中农立华生物科技股份有限公司利润 ...

| 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.2800 | 0.1400 | -300 | 0.7300 | | 每股净资产（元） | 16.28 | 16.93 | -3.84 | 16.86 | | 每股公积金(元) | 13.11 | 13.17 | -0.46 | 13.05 | | 每股未分配利润(元) | 2.48 | 2.76 | -10.14 | 2.81 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.42 | 2.58 | -6.2 | 4.24 | | 净利润(亿元) | -0.16 | 0.08 | -300 | 0.4 | | 净资产收益率(%) | -1.71 | 0.84 | -303.57 | 4.43 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2738.78万股，累计占流通股比： 49.04%，较上期变化： -21 ...

4月16日，之江生物今日收盘16.19元，下跌1.88%，最新市净率0.82，总市值31.11亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)17之江生物-24.40-24.400.8231.11亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 上海之江生物科技股份有限公司主营业务为分子诊断试剂及仪器设备的研发、生 ...

Core Viewpoint - The company reported a significant decline in its 2024 full-year performance, with revenue dropping by 11.6% to 5.371 billion yuan and net profit decreasing by 70.6% to 174 million yuan, indicating challenges in its skincare business and increased one-time costs related to strategic adjustments [1][2]. Financial Performance - For the full year of 2024, the company achieved revenue of 5.371 billion yuan, a decrease of 11.6%, and a net profit of 174 million yuan, down 70.6%. The adjusted net profit was 107 million yuan, reflecting a decline of 78.1% [1]. - In Q4 2024, revenue was 1.496 billion yuan, down 19.3%, with a net loss of 188 million yuan and an adjusted net loss of 219 million yuan [2]. Business Adjustments - The skincare business is undergoing a strategic repositioning, now named "Skin Science Innovation Transformation," with a focus on enhancing its biotechnology attributes. The revenue for the skincare segment is projected to decline by 31.6% to 2.569 billion yuan in 2024 [2][3]. - The company is initiating its third strategic upgrade, focusing on life sciences and restructuring its organization to enhance market responsiveness and problem-solving capabilities [3]. Growth Areas - The medical aesthetics segment is experiencing significant growth, with medical terminal business revenue reaching 1.44 billion yuan, up 32.0%, and skincare medical products revenue increasing by 43.6% to 1.073 billion yuan. The company expects continued growth in this area, particularly with new product approvals anticipated in H1 2025 [3]. - The raw materials business reported revenue of 1.236 billion yuan, an increase of 9.5%, with international raw material revenue growing by 17.7% to 608 million yuan [3]. Cost Structure - The company faced increased one-time costs due to strategic adjustments, including 70 million yuan in stock incentive consulting fees and over 100 million yuan in investments for innovative businesses. Inventory and goodwill impairments amounted to approximately 189 million yuan [2][4]. - The gross margin for 2024 was 73.6%, up 0.8 percentage points, driven by a higher proportion of high-margin pharmaceutical-grade products [4]. Future Outlook - The company is expected to see a recovery in its medical aesthetics business, driven by successful product launches and increased market penetration. The performance of the skincare business will be a critical indicator of the company's operational turnaround [5].

序号股票简称PE(TTM)PE(静)市净率总市值(元)3诺唯赞-558.56-558.562.56101.06亿行业平均 46.4449.384.75102.60亿行业中值30.3929.672.3746.63亿1天益医疗-2730.40-2730.401.7120.31亿2硕世生 物-1866.14-1866.141.1738.55亿4博晖创新-352.86-217.263.8954.16亿5康泰医学-269.6131.632.7552.44亿6 华大基因-201.20220.082.08204.46亿7奥精医疗-110.28-110.281.4119.98亿8睿昂基因-81.33-81.331.2611.76 亿9热景生物-62.30-62.303.43111.65亿10华大智造-53.01-53.013.98317.59亿11中红医疗-49.41- 33.620.7843.99亿 来源：金融界 南京诺唯赞生物科技股份有限公司的主营业务是围绕酶、抗原、抗体等功能性蛋白及高分子有机材料进 行技术研发和产品开发。公司的主要产品是生物试剂、诊断试剂、仪器设备、技术服务、耗材等材料。 最新一期业绩显示，2024年 ...

Core Viewpoint - The article highlights the significance of the fifth China International Consumer Products Expo (CICPE) as a platform for showcasing global consumer goods and promoting trade cooperation, particularly in the context of China's expanding market and the establishment of the Hainan Free Trade Port [2][6][10]. Group 1: Event Overview - The CICPE, held from April 13 to 18, features over 1,700 consumer enterprises and more than 4,100 brands from 71 countries and regions, with participation from 65 Fortune 500 companies [3][6]. - The event includes eight major exhibition halls focusing on various consumer trends such as technology, health, and green consumption [3][6]. Group 2: Economic and Trade Cooperation - The expo serves as a significant platform for deepening economic and trade cooperation, aiming for mutual benefits and enhanced interaction between global and Chinese enterprises [5][9]. - The Hainan Free Trade Port is expected to facilitate smoother trade and investment with policies like "zero tariffs, low tax rates, and simplified tax systems" [7][10]. Group 3: Consumer Market Insights - China's retail sales are projected to reach 48.8 trillion yuan in 2024, reflecting a 3.5% increase from the previous year, with a cumulative import of 7.4 trillion yuan in consumer goods from 2021 to 2024 [10][11]. - The government is focused on expanding domestic demand and enhancing consumer spending through various initiatives, including promoting consumption upgrades and organizing consumption activities [11][12]. Group 4: Participation of Global Brands - The UK is the guest country of honor at this year's expo, showcasing 53 brands, which is double the number from the previous year [16][17]. - Major global brands like Estée Lauder, Volkswagen, and Charoen Pokphand Group are participating, indicating the expo's role as a barometer for the Chinese consumer market [13][19]. Group 5: Innovations and New Products - The expo will feature a new consumption technology exhibition area, showcasing innovations from leading tech companies like Huawei and Tesla [18]. - Numerous listed companies are participating, with many launching new products, highlighting the vitality of the "first launch economy" [20][22].